慢性黏膜皮肤念珠菌病的治疗进展

Therapeutic progress of chronic mucocutaneous candidiasis disease

慢性黏膜皮肤念珠菌病(CMCD)是一种特殊类型的念珠菌感染,被认为是免疫缺陷相关性疾病,其发病机制复杂,治疗较为棘手。常规抗真菌药物已不能满足临床上对该病的治疗需求。随着研究发展,一些新型分子制剂对CMCD的治疗表现出巨大潜力。本文回顾了目前国内外对CMCD的治疗现状及未来的发展方向,以期为临床医生提供多重选择。

Chronic mucocutaneous candidiasis disease(CMCD)is a special type of Candida albicans infection,which is identified associated with immunodeficiency.The pathogenesis is complex and the treatment is more difficult.Conventional antifungal drugs have failed to meet the clinical demands.With the development of various treatment studies expanding,new molecular agents have shown great potential for the treatment of CMCD.This review summarizes the current status of treatment and future development of CMCD,in order to provide more information for clinicians.